Forum: Risks and rewards of gene editing
By Marcy Darnovsky,
Issues in Science and Technology
| 07. 31. 2020
In this interview as in past public comments, Jennifer Doudna opens the door to using the CRISPR platform she helped develop in the service of a hugely controversial enterprise: altering the genomes and traits of future children and subsequent generations. She does so under the banner of responsible science and policy. But as with similar comments by supporters of heritable genome manipulations, her responses shed little light on what criteria would constitute “responsible use,” how irresponsible uses could be avoided, and how this immensely consequential decision might be made in an open and democratically responsible way.
To be sure, Doudna notes that “the main challenge in embryo editing is not scientific … but rather ethical,” and raises important questions about the feasibility of consent by future generations, the difficulty of distinguishing between medical applications and enhancements, and the harm that eradicating genetic conditions might bring to people living with those conditions. But she gives no hint about how these challenges could be met. Tellingly, she fails to mention the broader social justice alarms about heritable genome editing: that the accumulation...
Related Articles
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...
By Rachel Hall, The Guardian | 11.20.2025
Couples are needlessly going through IVF because male infertility is under-researched, with the NHS too often failing to diagnose treatable causes, leading experts have said.
Poor understanding among GPs and a lack of specialists and NHS testing means male infertility...
By Pam Belluck and Carl Zimmer, The New York Times | 11.19.2025
Gene-editing therapies offer great hope for treating rare diseases, but they face big hurdles: the tremendous time and resources involved in devising a treatment that might only apply to a small number of patients.
A study published on Wednesday...
By Aisha Down, The Guardian | 11.10.2025
It has been an excellent year for neurotech, if you ignore the people funding it. In August, a tiny brain implant successfully decoded the inner speech of paralysis patients. In October, an eye implant restored sight to patients who had...